FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308138034> ?p ?o ?g. }

• W4308138034 endingPage "A176" @default.
• W4308138034 startingPage "A175" @default.
• W4308138034 abstract "Abstract Background The calcium sensing receptor (CASR) regulates parathyroid hormone secretion in response to extracellular calcium concentration. A gain-of-function mutation of the CASR lowers the set point for extracellular calcium sensing, resulting in both reduced parathyroid hormone secretion and increased urinary calcium excretion compared to other causes of hypoparathyroidism. Clinical Case After presenting with hypocalcemia-associated seizures at the age of two years, our patient had an undetectable serum parathyroid hormone level. He was started on calcitriol and calcium supplementation, however continued to have recurrent seizures throughout childhood. On ultrasound at age four, he exhibited nephrocalcinosis. DNA sequence analysis revealed a heterozygous T383G mutation nucleotide substitution on exon 3, resulting in the replacement of phenylalanine with cysteine at amino acid position 128. Our patient's base substitution likely represents a de novo mutation as we have confirmed that he has no family history of hypocalcemia. Notably, a different missense mutation at the same codon (F128L) co-segregated with autosomal dominant hypocalcemia in a large family, and functional studies confirm that mutation of this phenylalanine provides gain-of-function to the CASR. After enrolling in a clinical trial for continuous recombinant parathyroid hormone infusion at age seven, his symptoms of hypocalcemia abated. His seizures stopped, and anti-epileptic drugs were discontinued at age eight. After the clinical trial concluded, he was switched to teriparatide 10 micrograms three times daily, and serum calcium was maintained between 7.5 and 8.5 mg/dL. With the goal to minimize hypercalciuria and reduce the frequency of injections, teriparatide was discontinued, and recombinant parathyroid hormone (Natpara) 50 micrograms daily was started. This led to symptomatic hypocalcemia with muscle cramping and cognitive changes, and he was thus restarted on teriparatide with calcium carbonate supplementation. Despite maintenance of 24-hour urine calcium excretion ranging 325-388 mg, he developed bilateral flank pain. Computed tomography images revealed worsening nephrocalcinosis and bilateral nephrolithiasis. To reduce hypercalciuria and risk of stone formation, he was started on chlorthalidone, switched to calcium citrate, and encouraged to reduce dietary sodium intake. Conclusion This patient has a novel T383G activating mutation in CASR gene resulting in hypoparathyroidism and type 5 Bartter syndrome that has not been previously published in the literature. His hypocalcemia has remained stable on teriparatide for over 18 years, which to our knowledge, is the longest treatment duration using recombinant human parathyroid hormone for this purpose. We demonstrate a unique clinical challenge to balance treatment of hypoparathyroidism and hypocalcemia with teriparatide and supplemental calcium, while minimizing hypercalciuria and associated nephrocalcinosis. Presentation: No date and time listed" @default.
• W4308138034 created "2022-11-08" @default.
• W4308138034 creator A5009538484 @default.
• W4308138034 creator A5011483450 @default.
• W4308138034 creator A5078576628 @default.
• W4308138034 date "2022-11-01" @default.
• W4308138034 modified "2023-10-14" @default.
• W4308138034 title "ODP118 PTH (1-34) Replacement Therapy for Hypoparathyroidism due to Sporadic Calcium Sensing Receptor Gain-of-Function Point Mutation" @default.
• W4308138034 doi "https://doi.org/10.1210/jendso/bvac150.360" @default.
• W4308138034 hasPublicationYear "2022" @default.
• W4308138034 type Work @default.
• W4308138034 citedByCount "0" @default.
• W4308138034 crossrefType "journal-article" @default.
• W4308138034 hasAuthorship W4308138034A5009538484 @default.
• W4308138034 hasAuthorship W4308138034A5011483450 @default.
• W4308138034 hasAuthorship W4308138034A5078576628 @default.
• W4308138034 hasBestOaLocation W43081380341 @default.
• W4308138034 hasConcept C104317684 @default.
• W4308138034 hasConcept C126322002 @default.
• W4308138034 hasConcept C134018914 @default.
• W4308138034 hasConcept C142590548 @default.
• W4308138034 hasConcept C185592680 @default.
• W4308138034 hasConcept C2775941721 @default.
• W4308138034 hasConcept C2777308945 @default.
• W4308138034 hasConcept C2777724520 @default.
• W4308138034 hasConcept C2781208988 @default.
• W4308138034 hasConcept C501734568 @default.
• W4308138034 hasConcept C519063684 @default.
• W4308138034 hasConcept C55493867 @default.
• W4308138034 hasConcept C71924100 @default.
• W4308138034 hasConcept C75563809 @default.
• W4308138034 hasConceptScore W4308138034C104317684 @default.
• W4308138034 hasConceptScore W4308138034C126322002 @default.
• W4308138034 hasConceptScore W4308138034C134018914 @default.
• W4308138034 hasConceptScore W4308138034C142590548 @default.
• W4308138034 hasConceptScore W4308138034C185592680 @default.
• W4308138034 hasConceptScore W4308138034C2775941721 @default.
• W4308138034 hasConceptScore W4308138034C2777308945 @default.
• W4308138034 hasConceptScore W4308138034C2777724520 @default.
• W4308138034 hasConceptScore W4308138034C2781208988 @default.
• W4308138034 hasConceptScore W4308138034C501734568 @default.
• W4308138034 hasConceptScore W4308138034C519063684 @default.
• W4308138034 hasConceptScore W4308138034C55493867 @default.
• W4308138034 hasConceptScore W4308138034C71924100 @default.
• W4308138034 hasConceptScore W4308138034C75563809 @default.
• W4308138034 hasIssue "Supplement_1" @default.
• W4308138034 hasLocation W43081380341 @default.
• W4308138034 hasLocation W43081380342 @default.
• W4308138034 hasOpenAccess W4308138034 @default.
• W4308138034 hasPrimaryLocation W43081380341 @default.
• W4308138034 hasRelatedWork W1974087872 @default.
• W4308138034 hasRelatedWork W2040617300 @default.
• W4308138034 hasRelatedWork W2064236298 @default.
• W4308138034 hasRelatedWork W2095529129 @default.
• W4308138034 hasRelatedWork W2102487339 @default.
• W4308138034 hasRelatedWork W2126989082 @default.
• W4308138034 hasRelatedWork W2811478700 @default.
• W4308138034 hasRelatedWork W306911184 @default.
• W4308138034 hasRelatedWork W4308138034 @default.
• W4308138034 hasRelatedWork W1972645091 @default.
• W4308138034 hasVolume "6" @default.
• W4308138034 isParatext "false" @default.
• W4308138034 isRetracted "false" @default.
• W4308138034 workType "article" @default.